Cambium Bio Limited (ASX:CMB)

Australia · Delayed Price · Currency is AUD

0.4050

0.00 (0.00%)

Jul 14, 2026, 2:49 PM AEST

35.00% (1Y)

Market Cap	11.07M +113.7%
Revenue (ttm)	668.79K -19.1%
Net Income	-3.57M
EPS	-0.16
Shares Out	27.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173
Open	0.4050
Previous Close	0.4050
Day's Range	0.4050 - 0.4050
52-Week Range	0.2600 - 0.6000
Beta	-0.13
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Cambium Bio

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol CMB

Full Company Profile

Financial Performance

In fiscal year 2025, Cambium Bio's revenue was 774,882, an increase of 337.80% compared to the previous year's 176,995. Losses were -3.84 million, 70.4% more than in 2024.

Financial Statements